Condition: Neoplasms · Sponsor: Hoffmann-La Roche
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.
This description comes directly from the study's public registry record.
Reference Study ID Number: YO45758 https://forpatients.roche.com/ · 888-662-6728 (U.S.) · global-roche-genentech-trials@gene.com
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| University of Colorado - Anschutz Medical Campus - PPDS | Aurora, Colorado, United States | Recruiting |
| Smilow Cancer Hospital at Yale New Haven | New Haven, Connecticut, United States | Recruiting |
| Florida Cancer Specialists - Sarasota (North Catttlemen Rd) | Sarasota, Florida, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| South Texas Accelerated Research Therapeutics (START) | San Antonio, Texas, United States | Recruiting |
| St Vincent's Hospital Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| Peter MacCallum Cancer Center | Parkville, Victoria, Australia | Recruiting |
| Princess Margaret Hospital | Toronto, Ontario, Canada | Recruiting |
| Sun Yat-Sen University Cancer Center - Huangpu Campus | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-Sen University Cancer Center;Department of Thoracic Surgery | Guangzhou, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06884618